Insider Transactions in Q3 2025 at Roivant Sciences Ltd. (ROIV)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,341
-0.6%
|
$35,115
$15.17 P/Share
|
|
Sep 23
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
611,000
-28.88%
|
$8,554,000
$14.83 P/Share
|
|
Sep 22
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
416,182
-8.5%
|
$6,242,730
$15.0 P/Share
|
|
Sep 22
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
562,374
+9.89%
|
$1,687,122
$3.85 P/Share
|
|
Sep 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-0.54%
|
$31,935
$15.04 P/Share
|
|
Sep 19
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
683,818
-25.77%
|
$9,573,452
$14.95 P/Share
|
|
Sep 19
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000,000
+27.37%
|
$3,000,000
$3.85 P/Share
|
|
Sep 18
2025
|
Matthew Gline CEO |
BUY
Open market or private purchase
|
Direct |
3,315
+0.02%
|
$49,725
$15.07 P/Share
|
|
Sep 10
2025
|
Epperly Melissa B, |
SELL
Other acquisition or disposition
|
Direct |
1,661
-2.89%
|
$21,593
$13.77 P/Share
|
|
Sep 10
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+20.16%
|
-
|
|
Sep 10
2025
|
James C Momtazee |
SELL
Other acquisition or disposition
|
Direct |
3,282
-2.95%
|
$42,666
$13.77 P/Share
|
|
Sep 10
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+11.55%
|
-
|
|
Sep 10
2025
|
Ilan Oren |
SELL
Other acquisition or disposition
|
Direct |
2,043
-1.71%
|
$26,559
$13.77 P/Share
|
|
Sep 10
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+10.86%
|
-
|
|
Sep 10
2025
|
Meghan Fitzgerald |
SELL
Other acquisition or disposition
|
Direct |
937
-2.13%
|
$12,181
$13.77 P/Share
|
|
Sep 10
2025
|
Meghan Fitzgerald |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+24.86%
|
-
|
|
Sep 10
2025
|
Daniel Allen Gold |
SELL
Other acquisition or disposition
|
Direct |
5,270
-0.06%
|
$68,510
$13.77 P/Share
|
|
Sep 10
2025
|
Daniel Allen Gold |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+0.16%
|
-
|
|
Sep 10
2025
|
Keith S Manchester |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+0.74%
|
-
|
|
Sep 05
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
385,816
-1.07%
|
$4,629,792
$12.96 P/Share
|
|
Sep 04
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
194,933
-0.54%
|
$2,339,196
$12.92 P/Share
|
|
Sep 03
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,195,000
-3.21%
|
$14,340,000
$12.5 P/Share
|
|
Aug 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,340
-0.59%
|
$25,740
$11.94 P/Share
|
|
Aug 20
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
100,000
-5.7%
|
$1,100,000
$11.72 P/Share
|
|
Aug 20
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+5.4%
|
$300,000
$3.85 P/Share
|
|
Aug 20
2025
|
Eric Venker President & Immunovant CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,051
-0.42%
|
$77,561
$11.72 P/Share
|
|
Aug 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,235
-0.31%
|
$13,585
$11.72 P/Share
|
|
Jul 30
2025
|
Eric Venker President & Immunovant CEO |
BUY
Grant, award, or other acquisition
|
Direct |
198,413
+10.67%
|
-
|
|
Jul 30
2025
|
Frank Torti President and Vant Chair |
BUY
Grant, award, or other acquisition
|
Direct |
13,736,547
+48.21%
|
-
|
|
Jul 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,919
-0.48%
|
$21,109
$11.35 P/Share
|
|
Jul 21
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
100,000
-6.4%
|
$1,100,000
$11.52 P/Share
|
|
Jul 21
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+6.02%
|
$300,000
$3.85 P/Share
|
|
Jul 17
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,609
+3.61%
|
-
|
|
Jul 17
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
241
-0.25%
|
$2,651
$11.65 P/Share
|
|
Jul 17
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,201
+1.22%
|
-
|